{"filing":{"accession_number":"0001104659-26-091269","cik":"0001551152","ticker":"ABBV","company_name":"AbbVie Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-04","primary_document":"tm2621452d4_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926091269/tm2621452d4_8k.htm"},"events":[{"id":24217,"run_id":21929,"accession_number":"0001104659-26-091269","anchor_item_number":"8.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"AbbVie entered into an underwriting agreement on August 4, 2026, to issue approximately $9.93 billion in aggregate principal amount of senior notes across nine tranches with maturities ranging from 2028 to 2066. This is a material creation of direct financial obligations. The proceeds are earmarked to fund cash payment obligations for the Apogee Therapeutics acquisition and reduce a $10 billion delayed draw term loan facility, making this a significant financing event that would materially affect investor assessment of the company's capital structure and leverage.","company_name":"AbbVie Inc.","ticker":"ABBV","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":24694,"accession_number":"0001104659-26-091269","item_number":"8.01","item_title":"Other Events.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"AbbVie entered into an underwriting agreement on August 4, 2026, to issue approximately $9.93 billion in aggregate principal amount of senior notes across nine tranches with maturities ranging from 2028 to 2066. This is a material creation of direct financial obligations. The proceeds are earmarked to fund cash payment obligations for the Apogee Therapeutics acquisition and reduce a $10 billion delayed draw term loan facility, making this a significant financing event that would materially affect investor assessment of the company's capital structure and leverage.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T00:36:04.945846+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24694,"accession_number":"0001104659-26-091269","item_number":"8.01","item_title":"Other Events.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"AbbVie entered into an underwriting agreement on August 4, 2026, to issue approximately $9.93 billion in aggregate principal amount of senior notes across nine tranches with maturities ranging from 2028 to 2066. This is a material creation of direct financial obligations. The proceeds are earmarked to fund cash payment obligations for the Apogee Therapeutics acquisition and reduce a $10 billion delayed draw term loan facility, making this a significant financing event that would materially affect investor assessment of the company's capital structure and leverage.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T00:36:04.945846+00:00","company_name":"AbbVie Inc.","ticker":"ABBV","filing_date":"2026-08-05"}]}